HS-20093

DRUG15 trials

Sponsors

Hansoh BioMedical R&D Company, Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Advanced Prostate CancerAdvanced Solid TumorAdvanced Solid TumorsColorectal CancerExtensive Stage Small Cell Lung Cancer (ES-SCLC)Head and Neck Squamous Cell CarcinomaLimited-stage Small-cell Lung CancerMetastasis Castration Resistant Prostate Cancer(mCRPC)

Phase 1

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

RecruitingNCT06332170

Hansoh BioMedical R&D CompanyAdvanced Solid Tumor

Start: 2024-04-26End: 2028-05-30Target: 610Updated: 2024-07-18

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Not yet recruitingNCT06699576

Hansoh BioMedical R&D CompanyOsteosarcoma, Soft Tissue Sarcoma (STS)

Start: 2024-12-20End: 2028-12-30Target: 448Updated: 2024-11-21

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

RecruitingNCT06825624

Hansoh BioMedical R&D CompanyMetastatic Colorectal Cancer (CRC)

Start: 2024-10-03End: 2026-12-31Target: 560Updated: 2025-02-13

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Not yet recruitingNCT06963502

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer

Start: 2025-05-30End: 2030-04-30Target: 762Updated: 2025-05-09

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

RecruitingNCT07115446

Hansoh BioMedical R&D CompanyAdvanced Prostate Cancer

Start: 2025-08-19End: 2028-12-31Target: 63Updated: 2025-12-05

Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors

RecruitingNCT07186452

Hansoh BioMedical R&D CompanyAdvanced Solid Tumors

Start: 2025-09-23End: 2026-08-31Target: 18Updated: 2026-01-16

Phase 2

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

RecruitingNCT05830123

Hansoh BioMedical R&D CompanyOsteosarcoma, Sarcoma

Start: 2023-06-08End: 2027-12-31Target: 170Updated: 2024-08-23

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

RecruitingNCT06001255

Hansoh BioMedical R&D CompanyMetastasis Castration Resistant Prostate Cancer(mCRPC)

Start: 2024-01-18End: 2025-12-31Target: 120Updated: 2024-08-20

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

RecruitingNCT06007729

Hansoh BioMedical R&D CompanyHead and Neck Squamous Cell Carcinoma

Start: 2023-12-18End: 2027-12-12Target: 170Updated: 2024-08-20

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

WithdrawnNCT06052423

Hansoh BioMedical R&D CompanyExtensive Stage Small Cell Lung Cancer (ES-SCLC)

Start: 2024-11-30End: 2027-06-30Updated: 2024-03-04

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

RecruitingNCT06112704

Hansoh BioMedical R&D CompanyAdvanced Solid Tumor

Start: 2024-02-06End: 2026-12-31Target: 220Updated: 2024-12-02

Phase 3

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

RecruitingNCT06498479

Hansoh BioMedical R&D CompanySmall Cell Lung Cancer

Start: 2024-07-04End: 2027-05-31Target: 460Updated: 2024-10-16

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

Not yet recruitingNCT06526624

Hansoh BioMedical R&D CompanyLimited-stage Small-cell Lung Cancer

Start: 2024-09-30End: 2029-01-31Target: 406Updated: 2024-07-30

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Not yet recruitingNCT06935409

Hansoh BioMedical R&D CompanyOsteosarcoma

Start: 2025-04-30End: 2027-10-31Target: 117Updated: 2025-04-20

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Not yet recruitingNCT07464327

Hansoh BioMedical R&D CompanyNon-Small Cell Lung Cancer

Start: 2026-03-31End: 2029-12-31Target: 450Updated: 2026-03-11

Related Papers

A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.

Journal of Clinical Oncology2026-01-10

Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors

Cancer Research2025-04-25

A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.

Journal of Clinical Oncology2025-01-273 citations

ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma.

Journal of Clinical Oncology2024-06-0113 citations